Moving forward in LLIN distribution strategy: issues for discussion

Matthew Lynch
November 15, 2012
VCWG Continuous Distribution Workstream
Why?

- Current Strategic Framework is from 2005
- WHO position paper of 2007 emphasized scaling up
- In 2012 we’re in a different context
  - In 2005 the goal was reduced mortality among vulnerable populations
  - GMAP goal is elimination, implying a focus on transmission
LLIN context in 2012

• Success:
  – 5 years of massive scale-up
  – Many countries close to universal coverage, or at least at high rates of coverage

• Challenges:
  – Rapid changes in financial situation
  – Urgency to sustain the gains
What’s needed now

• Quantifying the gap- where are we short, and by how much?
• Mobilizing new sources of funds for LLIN ownership
• Targeting LLIN subsidies for maximum impact
  – On morbidity/mortality
  – On transmission
Mobilizing new resources

- New international donors - the BRICS?
- Endemic country governments
- Corporations in endemic countries
- Households in upper SES quintiles
Creating new efficiencies

• Lower-cost LLINs
• More efficient distribution channels and tools
• Targeting subsidies to those most in need, in terms of:
  – Ability to access and acquire nets
  – Risk of infection/parasitemia
Next Steps

• Quantifying key variables
  – Appropriate cost measures for comparison
  – Durability of LLINs in various contexts
  – Cost of applying subsidies through different methods

• Rebuilding the retail LLIN sector
  – Assessing what’s needed to bring the retail sector back in many countries
Next steps

• Establishing the evidence foundation for technical guidance on targeting LLINs
  – What are the key epidemiological parameters?
  – How should subsidies be targeted in support of epidemiology?
  – What are the best practices for applying targeted LLIN subsidies?
  – How do LLINs and targeted distribution fit into a broader IVM strategy?
Partners and Roles

• VCWG: facilitator and disseminator of experience, evidence and best practices
• GMP: evaluation of the evidence base and development of technical guidance
• LLIN manufacturers: assessment of barriers to commercial marketing and subsidized sales of LLINs